In Silico Prediction of BRCA1 and BRCA2 Variants with Conflicting Clinical Interpretation in a Cohort of Breast Cancer Patients
Genes · 2024
DOI: 10.3390/genes15070943 ↗Kurz gefasst
Fachartikel in der Zeitschrift Genes, 2024. Verfasst von Stefania Stella und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical and Experimental Medicine, University of Catania, 95123 Catania, Italy. Hauptthemen laut MEDLINE: Breast Neoplasms, BRCA2 Protein, BRCA1 Protein, Computer Simulation. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 55 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: European Union’s NextGenerationEU.
Themen: Onkologische Pflege
Abstract (Originalsprache)
Germline BRCA1/2 alteration has been linked to an increased risk of hereditary breast and ovarian cancer syndromes. As a result, genetic testing, based on NGS, allows us to identify a high number of variants of uncertain significance (VUS) or conflicting interpretation of pathogenicity (CIP) variants. The identification of CIP/VUS is often considered inconclusive and clinically not actionable for the patients’ and unaffected carriers’ management. In this context, their assessment and classification remain a significant challenge. The aim of the study was to investigate whether the in silico prediction tools (PolyPhen-2, SIFT, Mutation Taster and PROVEAN) could predict the potential clinical impact and significance of BRCA1/2 CIP/VUS alterations, eventually impacting the clinical management of Breast Cancer subjects. In a cohort of 860 BC patients, 10.6% harbored BRCA1 or BRCA2 CIP/VUS alterations, mostly observed in BRCA2 sequences (85%). Among them, forty-two out of fifty-five alterations were predicted as damaging, with at least one in silico that used tools. Prediction agreement of the four tools was achieved in 45.5% of patients. Moreover, the highest consensus was obtained in twelve out of forty-two (28.6%) mutations by considering three out of four in silico algorithms. The use of prediction tools may help to identify variants with a potentially damaging effect. The lack of substantial agreement between the different algorithms suggests that the bioinformatic approaches should be combined with the personal and family history of the cancer patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Clinical and Experimental Medicine, University of Catania, 95123 Catania, Italy.
- Center of Experimental Oncology and Hematology, A.O.U. Policlinico "G. Rodolico-San Marco", 95123 Catania, Italy.
- Department of General Surgery and Medical-Surgical Specialties, University of Catania, 95123 Catania, Italy.
- Division of Pathology, Humanitas Istituto Clinico Catanese, 95045 Catania, Italy.
- Medical Oncology Unit, Humanitas Istituto Clinico Catanese, 95045 Catania, Italy.
- Istituto Oncologico del Mediterraneo-IOM, 95029 Catania, Italy.
ORCID-Profile: Silvia Rita Vitale, Michele Massimino, Federica Martorana, Cristina Tomarchio
Förderung
- European Union’s NextGenerationEU
Zitieren
APA
Stella, S., Vitale, S. R., Massimino, M., Martorana, F., Tornabene, I., Tomarchio, C., Drago, M., Pavone, G., Gorgone, C., Barone, C., Bianca, S., & Manzella, L. (2024). In Silico Prediction of BRCA1 and BRCA2 Variants with Conflicting Clinical Interpretation in a Cohort of Breast Cancer Patients. Genes. https://doi.org/10.3390/genes15070943
Vancouver
Stella S, Vitale SR, Massimino M, Martorana F, Tornabene I, Tomarchio C, et al. In Silico Prediction of BRCA1 and BRCA2 Variants with Conflicting Clinical Interpretation in a Cohort of Breast Cancer Patients. Genes. 2024. doi:10.3390/genes15070943
BibTeX
@article{Stella2024,
author = {Stella, Stefania and Vitale, Silvia Rita and Massimino, Michele and Martorana, Federica and Tornabene, Irene and Tomarchio, Cristina and Drago, Melissa and Pavone, Giuliana and Gorgone, Cristina and Barone, Chiara and Bianca, Sebastiano and Manzella, Livia},
title = {In Silico Prediction of BRCA1 and BRCA2 Variants with Conflicting Clinical Interpretation in a Cohort of Breast Cancer Patients},
journal = {Genes},
year = {2024},
doi = {10.3390/genes15070943}
}
EUVIMED